Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025
Dec. 20, 2025 — Johnson & Johnson (NYSE: JNJ) is closing out the week with investors weighing a fresh talc-related jury verdict, a fast-moving U.S. drug-pricing policy push that could soon reach J&J, and a stream of late-2025 catalysts spanning